10:52 AM EDT, 07/23/2024 (MT Newswires) -- Virios Therapeutics ( VIRI ) said Tuesday that the Bateman Horne Center has concluded enrollment in its proof-of-concept long-COVID study.

The randomized, double-blind, placebo-controlled trial evaluates the combination of valacyclovir and celecoxib for treating fatigue and symptoms associated with long-COVID illness, the drugmaker said.

Virios said that top-line data from the study is expected to be released in October.

Shares of the company rose 8.2% in recent trading.

Price: 0.25, Change: +0.02, Percent Change: +8.24